HPV vaccination for prevention of skin cancer

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 2, 2015, Pages 353-357

  Vinzón, Sabrina E ^a   Rösl, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cutaneous papillomaviruses; Non melanoma skin cancer; Vaccination

Indexed keywords

ALPHA TOCOPHEROL; WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; FOOD INTAKE; HUMAN; META ANALYSIS; NOTE; OBSERVATIONAL STUDY; PANCREAS CANCER; QUALITY CONTROL; RISK ASSESSMENT; SCORING SYSTEM; VITAMIN INTAKE; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG DEVELOPMENT; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SKIN NEOPLASMS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SKIN NEOPLASMS;

EID: 84929070374     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.983858     Document Type: Note

References (61)

1. de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013; 445:2-10; PMID:23683837; http://dx.doi.org/10.1016/j.virol.2013.04.023
2. Grce M, Mravak-Stipetic M. Human papillomavirusassociated diseases. Clin Dermatol 2014; 32:253-8; PMID:24559561; http://dx.doi.org/10.1016/j. clindermatol.2013.10.006
3. Ma Y, Madupu R, Karaoz U, Nossa CW, Yang L, Yooseph S, Yachimski PS, Brodie EL, Nelson KE, Pei Z. Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets. J Virol 2014; 88:4786-97; PMID:24522917; http://dx.doi.org/10.1128/JVI.00093-14
4. Bruggink SC, de Koning MN, Gussekloo J, Egberts PF, Ter Schegget J, Feltkamp MC, Bavinck JN, Quint WG, Assendelft WJ, Eekhof JA. Cutaneous wart-associated HPV types: prevalence and relation with patient characteristics. J Clin Virol 2012; 55:250-5; PMID:22884670; http://dx.doi.org/10.1016/j.jcv.2012.07.014
5. Jablonska S, Majewski S, Obalek S, Orth G. Cutaneous warts. Clin Dermatol 1997; 15:309-19; PMID:9255438; http://dx.doi.org/10.1016/S0738-081X(96)00170-8
6. van Haalen FM, Bruggink SC, Gussekloo J, Assendelft WJ, Eekhof JA. Warts in primary schoolchildren: prevalence and relation with environmental factors. Br J Dermatol 2009; 161:148-52; PMID:19438464; http://dx.doi.org/10.1111/j.1365-2133.2009.09160.x
7. Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, Breitbart EW, Katalinic A. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 2014; 134:43-50; PMID:23877569; http://dx.doi.org/10.1038/jid.2013.304
8. Nindl I, R€osl F. Molecular concepts of virus infections causing skin cancer in organ transplant recipients. Am J Transplant 2008; 8:2199-204; PMID:18785959; http://dx.doi.org/10.1111/j.1600-6143.2008.02392.x
9. Wang J, Aldabagh B, Yu J, Arron ST. Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis. J Am Acad Dermatol 2014; 70:621-9; PMID:24629358; http://dx.doi.org/10.1016/j.jaad. 2014.01.857
10. Iannacone MR, Gheit T, Pfister H, Giuliano AR, Messina JL, Fenske NA, Cherpelis BS, Sondak VK, Roetzheim RG, Silling S, et al. Case-control study of genusbeta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. Int J Cancer 2014; 134:2231-44; PMID:24136717; http://dx.doi.org/10.1002/ijc.28552
11. Farzan SF, Waterboer T, Gui J, Nelson HH, Li Z, Michael KM, Perry AE, Spencer SK, Demidenko E, Green AC, et al. Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study. Int J Cancer 2013; 133:1713-20; PMID:23536363; http://dx.doi.org/10.1002/ijc.28176
12. Orth G. Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: guilty or innocent? J Invest Dermatol 2005; 125:12-13; PMID:15982294; http://dx.doi.org/10.1111/j.0022-202X.2005.23811.x
13. Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009; 73:348-70; PMID:19487731; http://dx.doi.org/10.1128/MMBR.00033-08
14. Schaper ID, Marcuzzi GP, Weissenborn SJ, Kasper HU, Dries V, Smyth N, Fuchs P, Pfister H. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005; 65:1394-400; PMID:15735026; http://dx.doi.org/10.1158/0008-5472.CAN-04-3263
15. Pfefferle R, Marcuzzi GP, Akgul B, Kasper HU, Schulze F, Haase I, Wickenhauser C, Pfister H. The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol 2008; 128:2310-5; PMID:18401427; http://dx.doi.org/10.1038/jid.2008.73
16. Borgogna C, Zavattaro E, De Andrea M, Griffin HM, Dell’Oste V, Azzimonti B, Landini MM, Peh WL, Pfister H, Doorbar J, et al. Characterization of beta papillomavirus E4 expression in tumours from Epidermodysplasia Verruciformis patients and in experimental models. Virology 2012; 423:195-204; PMID:22217391; http://dx.doi.org/10.1016/j.virol.2011.11.029
17. Harwood CA, Surentheran T, Sasieni P, Proby CM, Bordea C, Leigh IM, Wojnarowska F, Breuer J, McGregor JM. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol 2004; 150:949-57; PMID:15149508; http://dx.doi.org/10.1111/j.1365-2133.2004.05847.x
18. Pfister H. Chapter 8: human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003; 31:52-6; PMID:12807946; http://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a003483
19. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby CM. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61:289-97; PMID:10861635; http://dx.doi.org/10.1002/1096-9071(200007)61:3%3c289:: AID-JMV2%3e3.0.CO;2-Z20.
20. Borgogna C, Lanfredini S, Peretti A, De Andrea M, Zavattaro E, Colombo E, Quaglia M, Boldorini R, Miglio U, Doorbar J, et al. Improved detection reveals active beta-papillomavirus infection in skin lesions from kidney transplant recipients. Mod Pathol 2014; 27(8):1101-15; PMID:24390217
21. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, Majewski S, Pfister H, Wieland U. Human papillomavirus-DNA loads in actinic keratoses exceedthose in non-melanoma skin cancers. J Invest Dermatol 2005; 125:93-7; PMID:15982308; http://dx.doi.org/10.1111/j.0022-202X.2005.23733.x
22. Ak€gul B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol 2006; 208:165-75; PMID:16362995; http://dx.doi.org/10.1002/path.1893
23. Feltkamp MC, Broer R, Di Summa FM, Struijk L, van der Meijden E, Verlaan BP, Westendorp RG, Ter Schegget J, Spaan WJ, Bouwes Bavinck JN. Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res 2003; 63:2695-700; PMID:12750299
24. Struijk L, Hall L, van der Meijden E, Wanningen P, Bavinck JN, Neale R, Green AC, Ter Schegget J, Feltkamp MC. Markers of cutaneous human papillomavirus infection in individuals with tumor-free skin, actinic keratoses, and squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:529-35; PMID:16537712; http://dx.doi.org/10.1158/1055- 9965.EPI-05-0747
25. Plasmeijer EI, Pandeya N, O’Rourke P, Pawlita M, Waterboer T, Feltkamp MC, Green AC, Neale RE. The Association between Cutaneous Squamous Cell Carcinoma and Betapapillomavirus Seropositivity: a Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20:1171-7; PMID:21527580; http://dx.doi.org/10.1158/1055-9965.EPI-11-0110
26. Andersson K, Michael KM, Luostarinen T, Waterboer T, Gislefoss R, Hakulinen T, Forslund O, Pawlita M, Dillner J. Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. Am J Epidemiol 2012; 175:685-95; PMID:22419740; http://dx.doi.org/10.1093/aje/kwr373
27. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10:550-60; PMID:20592731; http://dx.doi.org/10.1038/nrc2886
28. Muschik D, Braspenning-Wesch I, Stockfleth E, R€osl F, Hofmann TG, Nindl I. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS One 2011; 6:e27655; PMID:22110707; http://dx.doi.org/10.1371/journal.pone.0027655
29. Wallace NA, Robinson K, Galloway DA. Beta human papillomavirus E6 expression inhibits stabilization of p53 and increases tolerance of genomic instability. J Virol 2014; 88:6112-27; PMID:24648447; http://dx.doi.org/10.1128/JVI.03808-13
30. White EA, Walther J, Javanbakht H, Howley PM. Genus Beta HPV E6 Proteins Vary in their Effects on the Transactivation of p53 Target Genes. J Virol 2014; 88(15):8201-12; PMID:24850740
31. Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19:592-8; PMID:10698529; http://dx.doi.org/10.1038/sj.onc.1203339
32. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 2008; 82:10408-17; PMID:18715924; http://dx.doi.org/10.1128/JVI.00902-08
33. Wallace NA, Robinson K, Howie HL, Galloway DA. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog 2012; 8:e1002807; PMID:22807682; http://dx.doi.org/10.1371/journal.ppat.1002807
34. Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, Londono-Vallejo JA, Tommasino M. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J 2008; 22:622-32; PMID:17898088; http://dx.doi.org/10.1096/fj.07-8389com
35. Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, G€rone H-J, Gheit T, Flechtenmacher C, Gissmann L, Tommasino M. E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice. PLoS Pathog 2011; 7:e1002125; PMID:21779166; http://dx.doi.org/10.1371/journal.ppat.1002125
36. Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011; 165:953-65; PMID:21729024; http://dx.doi.org/10.1111/j.1365-2133.2011.10507.x
37. Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010; 90:683-7; PMID:20808266; http://dx.doi.org/10.1097/TP. 0b013e3181ec7228
38. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992; 89:12180-4; PMID:1334560; http://dx.doi.org/10.1073/pnas.89. 24.12180
39. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
40. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8:390-7; PMID:22327492; http://dx.doi.org/10.4161/hv.18865
41. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012; 10:681-92; PMID:22961341; http://dx.doi.org/10.1038/nrmicro 2872
42. Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014; 134:2264-8; PMID:24174175; http://dx.doi.org/10.1002/ijc.28541
43. Senger T, Schadlich L, Textor S, Klein C, Michael KM, Buck CB, Gissmann L. Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine 2010; 28:1583-93; PMID:20003923; http://dx.doi.org/10.1016/j.vaccine.2009.11.048
44. Handisurya A, Gambhira R, Schellenbacher C, Shafti- Keramat S, Forslund O, Favre M, Kirnbauer R. Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. J Gen Virol 2009; 90:136-43; PMID:19088282; €
45. http://dx.doi.org/10.1099/vir.0.006189-0
46. Vinzon SE, Braspenning-Wesch I, M€uller M, Geissler EK, Nindl I, Gr€one HJ, Sch€afer K, R€osl F. Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model. PLoS Pathog 2014; 10:e1003924; PMID:24586150; http://dx.doi.org/10.1371/journal.ppat.1003924
47. Nafz J, Sch€afer K, Chen SF, Bravo IG, Ibberson M, Nindl I, Stockfleth E, R€osl F. A novel rodent papillomavirus isolated from anogenital lesions in its natural host. Virology 2008; 374:186-97; PMID:18234262; http://dx.doi.org/10.1016/j.virol.2007.12.012
48. Nafz J, K€ohler A, Ohnesorge M, Nindl I, Stockfleth E, R€osl F. Persistence of Mastomys natalensis papillomavirus in multiple organs identifies novel targets for infection. J Gen Virol 2007; 88:2670-8; PMID:17872518; http://dx.doi.org/10.1099/vir.0.82955-0
49. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13:857-61; PMID:17603495; http://dx.doi.org/10.1038/nm1598
50. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63; PMID:7745754
51. de Koning MN, Weissenborn SJ, Abeni D, Bouwes Bavinck JN, Euvrard S, Green AC, Harwood CA, Naldi L, Neale R, Nindl I, et al. Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol 2009; 90:1611-21; PMID:19321753; http://dx.doi.org/10.1099/vir.0.010017-0
52. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007; 81:13927-31; PMID:17928339; http://dx.doi.org/10.1128/JVI.00936-07
53. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RB. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 2008; 105:5850-5; PMID:18413606; http://dx.doi.org/10.1073/pnas.0800868105
54. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009; 101:782-92; PMID:19470949; http://dx.doi.org/10.1093/jnci/djp106
55. Tumban E, Peabody J, Peabody DS, Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011; 6: e23310; PMID:21858066; http://dx.doi.org/10.1371/journal.pone.0023310
56. Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, M€uller M, K€ellner M, Horer M. Development of AAVLP (HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate. PLoS One 2012; 7:e39741; PMID:22761884; http://dx.doi.org/10.1371/journal.pone.0039741
57. Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 2009; 83:10085-95; PMID:19640991; http://dx.doi.org/10.1128/JVI.01088-09
58. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Muller M, Ottonello S. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20–38) peptide displayed on bacterial thioredoxin. Vaccine 2009; 27:1949-56; PMID:19368776; http://dx.doi.org/10.1016/j.vaccine.2009.01.102
59. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 2013; 133:2706-13; PMID:23752042; http://dx.doi.org/10.1038/jid.2013. 253
60. Kwak K, Jiang R, Wang JW, Jagu S, Kirnbauer R, Roden RB. Impact of Inhibitors and L2 Antibodies upon the Infectivity of Diverse Alpha and Beta Human Papillomavirus Types. PLoS One 2014; 9:e97232; PMID:24816794; http://dx.doi.org/10.1371/journal.pone.0097232
61. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT. In vivo mechanisms of vaccine- induced protection against HPV infection. Cell Host Microbe 2010; 8:260-70; PMID:20833377; http://dx.doi.org/10.1016/j.chom.2010.08.003